27, 1% placebo) og den samlede mortalitets - og morbiditetsrisiko blev signifikant reduceret med 44% (24, 9% valsartan vs.
27.1% placebo) and the composite mortality and morbidity risk was significantly reduced by 44% (24.9% valsartan vs.